Combined use of biochemical markers in predicting pre-eclampsia
Research type
Research Study
Full title
Can the combined use of biochemical markers improve the prediction of pre-eclampsia?
IRAS ID
298682
Contact name
Amy Kiley
Contact email
Sponsor organisation
Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust
Duration of Study in the UK
1 years, 11 months, 30 days
Research summary
Pre-eclampsia affects approximately 2-8% of pregnancies. The condition involves high blood pressure occurring after 20 weeks of pregnancy, in combination with protein in the urine or other evidence of kidney, liver, brain or blood problems. It can lead to serious complications for both the mother and developing fetus.
Traditionally diagnosis involves measuring blood pressure and protein in urine, however these tests can miss some women who develop pre-eclampsia and falsely identify some women who do not.
Women with pre-eclampsia need close monitoring, often in hospital, so better tests are required in order to ensure women are correctly identified for close monitoring and supportive treatment.
Studies have shown that the ratio of two proteins in the mother’s blood, sFlt-1 and PlGF, can help to predict whether or not a women will develop pre-eclampsia.
This study aims to show whether adding the measurement of two other proteins in the mother’s blood, NT-proBNP and PAPP-A, rather than the ratio of sFlt-1 and PlGF alone, can improve our ability to identify women most at risk whilst reducing hospital stays and appointments for those who are not.
REC name
Wales REC 5
REC reference
22/WA/0103
Date of REC Opinion
4 Apr 2022
REC opinion
Favourable Opinion